Akari Therapeutics, Plc (AKTX) vs Johnson & Johnson (JNJ)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AKTX | JNJ | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | NANO | MEGA |
| Listing | Nasdaq CM | NYSE |
| Country | United States | United States |
| Theme | oncology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $7.63 | $266.30 |
| Return · 1 week | −22.85% | +4.93% |
| Return · 1 month | −22.22% | −2.08% |
| Return · 3 months | −9.49% | −0.16% |
| Return · year to date | −34.22% | +29.86% |
| Return · 1 year | −75.98% | +42.39% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −77.29% | −5.25% |
| 52-week high | $33.60 | $281.07 |
| 52-week low | $3.02 | $184.66 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $17.44M | $641.07B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $418.51K | $1.64B |
| Employees | 5 | 138,200 |
| Valuation | ||
| Price to earnings · trailing | — | 30.29× |
| Price to earnings · forward | n/a (negative forward earnings) | 21.54× |
| Price to sales | — | 6.43× |
| Price to book | 0.83× | 7.41× |
| Enterprise value to EBITDA | — | 18.67× |
| Enterprise value to revenue | — | 6.65× |
| PEG ratio | — | 2.67 |
| Earnings per share · trailing | 0.00 | 8.63 |
| Profitability | ||
| Gross margin | — | 67.91% |
| Operating margin | 0.00% | 29.19% |
| Profit margin | — | 21.48% |
| Return on equity | −140.09% | 25.74% |
| Return on assets | −19.10% | 8.60% |
| Growth | ||
| Revenue growth | — | +6.60% |
| Earnings growth | — | −0.90% |
| Balance sheet and payout | ||
| Debt / equity (%) | 3.73 | 57.71 |
| Current ratio | 0.60 | 1.09 |
| Dividend yield | 0.00% | 2.09% |
| Payout ratio | 0.00% | 60.72% |
| Trend and volatility | ||
| RSI · 14 | 42.02 | 55.33 |
| ADX · 14 | 15.41 | 15.50 |
| 50-day average | $9.23 | $265.32 |
| 200-day average | $9.11 | $245.78 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 13.02% | 2.75% |
The full AKTX analysis
Everything this table leaves out for Akari Therapeutics, Plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AKTX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AKTX analysisThe full JNJ analysis
Everything this table leaves out for Johnson & Johnson: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the JNJ argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full JNJ analysis